Authors: Hood S.D.; Argyropoulos S.V.; Nutt D.J.

Source: Expert Opinion on Therapeutic Patents, Volume 13, Number 4, 1 April 2003 , pp. 401-423(23)

Publisher: Informa Healthcare

Abstract:

Despite significant advances in the treatment of anxiety disorders in recent times, limitations such as suboptimal efficacy, side effects and delay of clinical effect remain. Ongoing research conducted within the boundaries of the existing psychiatric nomenclature is producing real improvements in our understanding of these prevalent and impairing conditions. A broadening of our understanding of both classical and contemporary neurotransmitter systems, in addition to the disorder-specific knowledge base, is informing new directions for anxiety disorder treatments. This article reviews patent activity for anxiolytic compounds released since 2000 within both anxiety disorderspecific and neurotransmitter-specific contexts.

Keywords: 5-hydroxytryptamine (5-HT); anxiety; cannabinoid; conopeptide; GABAA; glutamateN-acetylated--linked acidic dipeptidase (NAALADase); neurokinin; neuropeptide; novel; patent; serotonin; treatment

Document Type: Review article

Publication date: 2003-04-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Hood S.D. ;  Argyropoulos S.V. ;  Nutt D.J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers